Aficamten

53 interactions 17 cited references

Read the full Aficamten drug information page

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Major

Aficamten Apalutamide Erleada Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Bosentan Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Aficamten Carbamazepine Carbatrol Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Cenobamate Xcopri Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Dabrafenib Tafinlar Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Dipyrone Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Doxifluridine Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Aficamten Efavirenz Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Elagolix Orilissa Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Encorafenib Braftovi Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Enzalutamide Xtandi Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Aficamten Etravirine Intelence Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Fluconazole Diflucan Increased aficamten exposure and an increased risk of aficamten-related adverse reaction Details Aficamten Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Aficamten Fluvoxamine Increased aficamten exposure and an increased risk of aficamten-related adverse reaction Details Aficamten Fosphenytoin Cerebyx Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Ivosidenib Tibsovo Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Lesinurad Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Lopinavir Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Lorlatinib Lorbrena Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Lumacaftor Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Lumefantrine Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Aficamten Mitapivat Aqvesme Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Mitotane Lysodren Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Modafinil Provigil Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Nafcillin Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Aficamten Pacritinib Vonjo® Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Pexidartinib Turalio Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Phenobarbital Fidoquel Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Phenytoin Dilantin Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Primidone Mysoline Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Aficamten Repotrectinib Augtyro Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Rifabutin Mycobutin Reduced aficamten exposure and reduced efficacy of aficamten Details Aficamten Rifapentine Priftin Reduced aficamten exposure and reduced efficacy of aficamten Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.